Eli Lilly and Company (NYSE:LLY) Position Increased by Legacy Financial Strategies LLC

Legacy Financial Strategies LLC raised its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 9.6% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 694 shares of the company’s stock after buying an additional 61 shares during the period. Legacy Financial Strategies LLC’s holdings in Eli Lilly and Company were worth $540,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in LLY. Acadian Asset Management LLC boosted its holdings in Eli Lilly and Company by 15.1% during the third quarter. Acadian Asset Management LLC now owns 49,715 shares of the company’s stock worth $26,697,000 after buying an additional 6,528 shares in the last quarter. LPL Financial LLC boosted its stake in Eli Lilly and Company by 20.9% in the 3rd quarter. LPL Financial LLC now owns 595,387 shares of the company’s stock worth $319,804,000 after purchasing an additional 102,734 shares during the period. Fuller & Thaler Asset Management Inc. boosted its stake in Eli Lilly and Company by 7.0% in the 3rd quarter. Fuller & Thaler Asset Management Inc. now owns 3,054 shares of the company’s stock worth $1,640,000 after purchasing an additional 200 shares during the period. Retirement Planning Co of New England Inc. boosted its stake in Eli Lilly and Company by 12.6% in the 3rd quarter. Retirement Planning Co of New England Inc. now owns 2,759 shares of the company’s stock worth $1,482,000 after purchasing an additional 309 shares during the period. Finally, Northern Trust Corp boosted its stake in Eli Lilly and Company by 3.6% in the 3rd quarter. Northern Trust Corp now owns 10,158,275 shares of the company’s stock worth $5,456,314,000 after purchasing an additional 355,317 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently commented on LLY. Jefferies Financial Group raised their price objective on shares of Eli Lilly and Company from $925.00 to $957.00 and gave the stock a “buy” rating in a research note on Friday, June 7th. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Truist Financial raised their price objective on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a research note on Wednesday, May 1st. Argus raised their price objective on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a research note on Tuesday, May 14th. Finally, The Goldman Sachs Group increased their target price on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $803.50.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 2,052 shares of Eli Lilly and Company stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $809.00, for a total value of $1,660,068.00. Following the transaction, the insider now owns 98,554,195 shares in the company, valued at approximately $79,730,343,755. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Eli Lilly and Company news, EVP Johna Norton sold 7,056 shares of the firm’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $819.38, for a total value of $5,781,545.28. Following the sale, the executive vice president now directly owns 25,428 shares in the company, valued at approximately $20,835,194.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Lilly Endowment Inc sold 2,052 shares of the firm’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $809.00, for a total transaction of $1,660,068.00. Following the completion of the sale, the insider now owns 98,554,195 shares in the company, valued at $79,730,343,755. The disclosure for this sale can be found here. Insiders have sold 762,804 shares of company stock worth $648,109,138 in the last quarter. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Stock Down 0.2 %

Eli Lilly and Company stock opened at $884.46 on Friday. The company has a market capitalization of $840.60 billion, a P/E ratio of 130.26, a P/E/G ratio of 1.93 and a beta of 0.36. The firm’s fifty day simple moving average is $798.59 and its 200-day simple moving average is $727.93. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. Eli Lilly and Company has a 1-year low of $434.34 and a 1-year high of $905.45.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The business had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. Eli Lilly and Company’s revenue for the quarter was up 26.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.62 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 13.76 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, June 10th. Stockholders of record on Thursday, May 16th were issued a dividend of $1.30 per share. The ex-dividend date of this dividend was Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.59%. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.